1. Martinez MJ, BonfiLL X, Moreno RM, Vargas E, CapeLLa D. Phiebotonics for venous insufficiency. Cochrane Database Syst Rev, 2005: CD003229.
2. RameLet AA, Boisseau MR, ALLegra C, NicoLaides A, Jaeger K, Carpentier P et aL. Veno-active drugs in the management of chronic venous disease. An internationaL consensus statement: current medicaL position, prospective views and final resoLution. Clin Hemorheol Microcirc, 2005, 33: 309-319.
3. PittLer MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev, 2012, 11: CD003230.
4. Barbe R, AmieL M. Pharmacodynamic properties and therapeutic efficacy of DafLon 500 mg. Phlebology, 1992, 7: 41-44.
5. BLume J, Langenbahn H, de ChampvaLLins M. Quantification of oedema using the voLometer technique: therapeutic appLication of DafLon 500 mg in chronic venous insufficiency. Phlebology, 1992, 7: 37-40.
6. GaLLey P, ThioLLet M. A doubLe-bLind, pLacebo-controLLed triaL of a new veno-active fLavonoid fraction (S 5682) in the treatment of symptomatic capiLLary fragiLity. Int Angiol, 1993, 12: 69-72.
7. GiLLy R, PiLLion G, FriLeux C. EvaLuation of a new veno-active micronized fLavonoid fraction (S5682) in symptomatic disturbances of the venoLymphatic circuLation of the Lower Limb. A doubLe-bLinded, pLacebo-controLLed triaL. Phlebology, 1994, 9: 67-70.
8. ALLaert FA. Meta-anaLysis of the impact of the principaL venoactive drugs agents on maLLeoLar venous edema. Int Angiol, 2012, 31: 310-315.
9. Jantet G. Chronic venous insufficiency: worLdwide resuLts of he RELIEF study. RefLux assEssment and quaLity of Life mprovEment with micronized FLavonoids. Angiology, 2002, 53: 245-256.
10. GoheL MS, Davies AH. PharmacoLogicaL agents in the treatment of venous disease: an update of the avaiLabLe evidence. Curr Vasc Pharmacol, 2009, 7: 303-308.
11. Rabe E, Jaeger KA, BuLitta M, Pannier F. CaLcium dobesiLate in patients suffering from chronic venous insufficiency: a doubLe-bLind, pLacebo-controLLed, cLinicaL triaL. Phlebology, 2011, 26: 162-168.
12. Rabe E, Stucker M, Esperester A, Schafer E, OttiLLinger B. Efficacy and toLerabiLity of a red-vine-Leaf extract in patients suffering from chronic venous insufficiency e resuLts of a doubLe-bLind pLacebo-controLLed study. Eur J Vasc Endovasc Surg, 2011, 41: 540-547.
13. JuLL AB, ArroLL B, Parag V, Waters J. PentoxifyLLine for treating venous Leg uLcers. Cochrane Database Syst Rev, 2012, 12: CD001733.
14. DaLe JJ, RuckLey CV, Harper DR, Gibson B, NeLson EA, Prescott RJ. Randomised, doubLe bLind pLacebo controLLed triaL of pen-toxifyLLine in the treatment of venous Leg uLcers. Br Med J, 1999, 319: 875-878.
15. FaLanga V, Fujitani RM, Diaz C, Hunter G, Jorizzo J, Lawrence PF, et aL. Systemic treatment of venous Leg uLcers with high doses of pentoxifyLLine: efficacy in a randomized, pLacebo-controLLed triaL. Wound Repair Regen, 1999, 7: 208-213.
16. NeLson EA, Prescott RJ, Harper DR, Gibson B, Brown D, RuckLey CV. A factoriaL, randomized triaL of pentoxifyLLine or pLacebo, four-Layer or singLe-Layer compression, and knitted viscose or hydrocoLLoid dressings for venous uLcers. J Vasc Surg, 2007, 45: 134-141.
17. Layton AM, Ibbotson SH, Davies JA, GoodfieLd MJ. Randomised triaL of oraL aspirin for chronic venous Leg uLcers. Lancet, 1994, 344: 164-165.
18. Ibbotson SH, Layton AM, Davies JA, GoodfieLd MJ. The effect of aspirin on haemostatic activity in the treatment of chronic venous Leg uLceration. Br J Dermatol, 1995, 132: 422-426.
19. deL Rio SoLa ML, Antonio J, Fajardo G, Vaquero Puerta C. Influence of aspirin therapy in the uLcer associated with chronic venous insufficiency. Ann Vasc Surg, 2012, 26: 620629.
20. WiLkinson EA, Hawke CI. Does oraL zinc aid the heaLing of chronic Leg uLcers? A systematic Literature review. Arch Dermatol, 1998, 134: 1556-1560.
21. O'Meara S, AL-Kurdi D, OLogun Y, Ovington LG. Antibiotics and antiseptics for venous Leg uLcers. Cochrane Database Syst Rev, 2010: CD003557.
22. Andreozzi GM. SuLodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs, 2012, 12: 73-81.
23. Leach MJ, Pincombe J, Foster G. CLinicaL efficacy of horsechest-nut seed extract in the treatment of venous uLceration. J Wound Care, 2006, 15: 159-167.
24. GuiLhou JJ, Dereure 0, Marzin L, Ouvry P, ZuccareLLi F, Debure C et aL. Efficacy of DafLon 500 mg in venous Leg uLcer heaLing: a doubLe-bLind, randomized, controLLed versus pLacebo triaL in 107 patients. Angiology, 1997, 48: 77-85.
25. GLinski W, Chodynicka B, Roszkiewicz J, Bogdanowski T, Lecewicz-Torun B, Kaszuba A, et aL. The beneficiaL augmentative effect of micronozed purified fLavonoid fraction (MPFF) on the heaLing of Leg uLcers: an open, muLicentre, controLLed randomised study. Phlebology, 1999, 14: 151-157.
26. RoztociL K, Stvrtinova V, Strejcek J. Efficacy of a 6-month treatment with DafLon 500 mg in patients with venous Leg uLcers associated with chronic venous insufficiency. Int Angiol, 2003, 22: 24-31.
27. ScaLLon C, BeLL-Syer SE, Aziz Z. FLavonoids for treating venous Leg uLcers. Cochrane Database Syst Rev, 2013, 5: CD006477.
28. CoLeridge-Smith P, Lok C, RameLet AA. Venous Leg uLcer: a meta-anaLysis of adjunctive therapy with micronized purified fLavonoid fraction. Eur J Vasc Endovasc Surg, 2005, 30: 198208.
29. Wittens C, Davies AH, Baekgaard N et aL. Management of Chronic Venous Disease. CLinicaL Practice GuideLines of the European Society for VascuLar Surgery (ESVS). Eur J Vasc Endovasc Surg, 2015, 49: 678-737.
Послать статью по эл. почте 